系统解读：5大策略破解抑制性肿瘤微环境，助力CAR-T细胞攻克实体瘤

Core Viewpoint - CAR-T cell therapy has achieved significant success in treating hematological cancers, but faces numerous challenges in solid tumors, including T cell exhaustion, off-target toxicity, and the immunosuppressive tumor microenvironment [2] Group 1: Challenges in CAR-T Cell Therapy - T cell exhaustion leads to decreased anti-tumor activity, while "on target off tumor" toxicity can harm normal cells [2] - The solid tumor microenvironment is characterized by hypoxia and immunosuppressive cells and molecules, which inhibit CAR-T cell immune responses and hinder their localization and infiltration [2] Group 2: Advances in CAR-T Cell Therapy - Recent research highlights various strategies to enhance CAR-T cell therapy for solid tumors, including immune checkpoint inhibition, targeted antigen selection, gene editing, dual-targeting, and combination therapies [2] - Blocking PD-1 signaling can enhance CAR-T cell persistence and reduce T cell exhaustion, with methods such as PD-1 antibodies and shRNA showing promise [4] - Combining CAR-T cell therapy with local CD47 blockade can reverse immune suppression in the tumor microenvironment [4] Group 3: Cytokine Engineering - Cytokine engineering of CAR-T cells is a promising strategy to overcome limitations in solid tumors, with membrane-bound IL-12 and IL-15 enhancing anti-tumor efficacy and T cell proliferation [8] - IL-18 can improve T cell and NK cell activity, with engineered CAR-T cells showing significant anti-tumor effects in mouse models [8] Group 4: Targeting Tumor Microenvironment - Targeting the TGF-β pathway can alleviate T cell exhaustion and excessive cytokine release, making it a potential target for optimizing CAR-T cell therapy [9] - The extracellular matrix (ECM) poses a barrier to CAR-T cell infiltration, with new technologies enabling CAR-T cells to degrade ECM and improve their infiltration capabilities [11] Group 5: Gene Editing and Multi-Design Approaches - Gene editing strategies, such as knocking down multiple inhibitory factors, have been shown to enhance CAR-T cell activity against cholangiocarcinoma [13] - The development of dual-target CAR-T cells targeting EGFR and IL-13R α 2 has demonstrated improved survival rates in glioma models [9] Group 6: Industry Support - Companies like Yiqiao Shenzhou provide high-purity and high-activity target proteins to support CAR-T cell development, utilizing advanced membrane protein technology platforms [14]